Literature DB >> 24011831

Treatment of Shiga toxin-producing Escherichia coli infections.

T Keefe Davis1, Ryan McKee, David Schnadower, Phillip I Tarr.   

Abstract

The management of Shiga toxin-producing Escherichia coli (STEC) infections is reviewed. Certain management practices optimize the likelihood of good outcomes, such as avoidance of antibiotics during the pre-hemolytic uremic syndrome phase, admission to hospital, and vigorous intravenous volume expansion using isotonic fluids. The successful management of STEC infections is based on recognition that a patient might have an STEC infection, and appropriate use of the microbiology laboratory. The timeliness of STEC identification cannot be overemphasized, because it avoids therapies prompted by inappropriate additional testing and directs the clinician to focus on effective management strategies. The opportunities during STEC infections to avert the worst outcomes are brief, and this article emphasizes practical matters relevant to making a diagnosis, anticipating the trajectory of illness, and optimizing care.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibiotics; Escherichia coli O157:H7; Hemolytic uremic syndrome; Microbiologic diagnosis; Shiga-toxin

Mesh:

Substances:

Year:  2013        PMID: 24011831     DOI: 10.1016/j.idc.2013.05.010

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  21 in total

1.  Baicalin inhibits the lethality of Shiga-like toxin 2 in mice.

Authors:  Jing Dong; Yong Zhang; Yutao Chen; Xiaodi Niu; Yu Zhang; Cheng Yang; Quan Wang; Xuemei Li; Xuming Deng
Journal:  Antimicrob Agents Chemother       Date:  2015-09-08       Impact factor: 5.191

2.  Real-Time PCR Assay for Detection and Differentiation of Shiga Toxin-Producing Escherichia coli from Clinical Samples.

Authors:  Xuan Qin; Eileen J Klein; Emmanouil Galanakis; Anita A Thomas; Jennifer R Stapp; Shannon Rich; Anne Marie Buccat; Phillip I Tarr
Journal:  J Clin Microbiol       Date:  2015-04-29       Impact factor: 5.948

3.  Case definitions of hemolytic uremic syndrome following Escherichia coli O157:H7 infection vary in validity.

Authors:  Gillian A M Tarr; Hanna N Oltean; Amanda I Phipps; Peter Rabinowitz; Phillip I Tarr
Journal:  Int J Med Microbiol       Date:  2018-10-10       Impact factor: 3.473

4.  Protection against Shiga-Toxigenic Escherichia coli by Non-Genetically Modified Organism Receptor Mimic Bacterial Ghosts.

Authors:  Adrienne W Paton; Austen Y Chen; Hui Wang; Lauren J McAllister; Florian Höggerl; Ulrike Beate Mayr; Lucy K Shewell; Michael P Jennings; Renato Morona; Werner Lubitz; James C Paton
Journal:  Infect Immun       Date:  2015-06-22       Impact factor: 3.441

5.  Hyperuricemia: an unrecognized risk factor for kidney-related sequelae in children with hemolytic uremic syndrome.

Authors:  Alejandro Balestracci; Luciana Meni Battaglia; Ismael Toledo; Laura Beaudoin; Sandra Mariel Martin; Nicolás Ariel Grisolía; Ronald J Hogg
Journal:  Pediatr Nephrol       Date:  2022-10-13       Impact factor: 3.651

6.  Erythropoietin in children with hemolytic uremic syndrome: a pilot randomized controlled trial.

Authors:  Alejandro Balestracci; Marina Andrea Capone; Luciana Meni Battaglia; Ismael Toledo; Sandra Mariel Martin; Laura Beaudoin; Jeanette Balbaryski; Lorena Gómez
Journal:  Pediatr Nephrol       Date:  2022-02-15       Impact factor: 3.651

7.  Phenethyl isothiocyanate inhibits shiga toxin production in enterohemorrhagic Escherichia coli by stringent response induction.

Authors:  Dariusz Nowicki; Monika Maciąg-Dorszyńska; Wioletta Kobiela; Anna Herman-Antosiewicz; Alicja Węgrzyn; Agnieszka Szalewska-Pałasz; Grzegorz Węgrzyn
Journal:  Antimicrob Agents Chemother       Date:  2014-02-03       Impact factor: 5.191

8.  Strength of the association between antibiotic use and hemolytic uremic syndrome following Escherichia coli O157:H7 infection varies with case definition.

Authors:  Gillian A M Tarr; Hanna N Oltean; Amanda I Phipps; Peter Rabinowitz; Phillip I Tarr
Journal:  Int J Med Microbiol       Date:  2018-06-26       Impact factor: 3.473

9.  A universal polysaccharide conjugated vaccine against O111 E. coli.

Authors:  Gabrielle R Andrade; Roger R C New; Osvaldo A Sant'Anna; Neil A Williams; Rosely C B Alves; Daniel C Pimenta; Hugo Vigerelli; Bruna S Melo; Letícia B Rocha; Roxane M F Piazza; Lucia Mendonça-Previato; Marta O Domingos
Journal:  Hum Vaccin Immunother       Date:  2014-11-21       Impact factor: 3.452

10.  A Poly-N-acetylglucosamine-Shiga toxin broad-spectrum conjugate vaccine for Shiga toxin-producing Escherichia coli.

Authors:  Xi Lu; David Skurnik; Clarissa Pozzi; Damien Roux; Colette Cywes-Bentley; Jennifer M Ritchie; Diana Munera; Marina L Gening; Yury E Tsvetkov; Nikolay E Nifantiev; Matthew K Waldor; Gerald B Pier
Journal:  MBio       Date:  2014-03-25       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.